intracellular stage
Recently Published Documents


TOTAL DOCUMENTS

19
(FIVE YEARS 2)

H-INDEX

10
(FIVE YEARS 0)

2021 ◽  
Author(s):  
Rebecca L Pedler ◽  
James Harris ◽  
Peter G Speck

Coronaviruses can can cause severe respiratory infections in humans. This study aimed to assess the antiviral activity of Pacific oyster (Crassostrea gigas) hemolymph against a human coronavirus, HCoV-229E. An eight-fold reduction in infectivity of HCoV-229E on Huh-7 cells was observed in the presence of 10% C. gigas hemolymph. Antiviral activity of C. gigas hemolymph positively correlated with its concentration and appears to be active during an intracellular stage of HCoV-229E infection.


npj Vaccines ◽  
2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Sarah M. Baker ◽  
Erik W. Settles ◽  
Christopher Davitt ◽  
Patrick Gellings ◽  
Nicole Kikendall ◽  
...  

AbstractBurkholderia pseudomallei is a Gram-negative, facultative intracellular bacillus that causes the disease melioidosis. B. pseudomallei expresses a number of proteins that contribute to its intracellular survival in the mammalian host. We previously demonstrated that immunization with OMVs derived from B. pseudomallei grown in nutrient-rich media protects mice against lethal disease. Here, we evaluated if OMVs derived from B. pseudomallei grown under macrophage-mimicking growth conditions could be enriched with intracellular-stage proteins in order to improve the vaccine. We show that OMVs produced in this manner (M9 OMVs) contain proteins associated with intracellular survival yet are non-toxic to living cells. Immunization of mice provides significant protection against pulmonary infection similar to that achieved with a live attenuated vaccine and is associated with increased IgG, CD4+, and CD8+ T cells. OMVs possess inherent adjuvanticity and drive DC activation and maturation. These results indicate that M9 OMVs constitute a new promising vaccine against melioidosis.


Author(s):  
Carlos Medina ◽  
Beatriz Mesa-Pereira ◽  
Eva M. Camacho ◽  
Amando Flores ◽  
Eduardo Santero

2014 ◽  
Vol 209 (8) ◽  
pp. 1288-1296 ◽  
Author(s):  
Fernanda O. Novais ◽  
Ba T. Nguyen ◽  
Daniel P. Beiting ◽  
Lucas P. Carvalho ◽  
Nelson D. Glennie ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Matilde Jimenez-Coello ◽  
Karla Y. Acosta-Viana ◽  
Antonio Ortega-Pacheco ◽  
Salud Perez-Gutierrez ◽  
Eugenia Guzman-Marin

In order to evaluate the antiprotozoal activity of the chloroform extract ofCarica papayaseeds during the subacute and chronic phase of infection ofTrypanosoma cruzi, doses of 50 and 75 mg/kg were evaluated during the subacute phase, including a mixture of their main components (oleic, palmitic, and stearic acids). Subsequently, doses of 50 and 75 mg/kg in mice during the chronic phase of infection (100 dpi) were also evaluated. It was found that chloroform extract was able to reduce the amastigote nests numbers during the subacute phase in 55.5 and 69.7% (P> 0.05) as well as in 56.45% in animals treated with the mixture of fatty acids. Moreover, the experimental groups treated with 50 and 75 mg/kg during the chronic phase of the infection showed a significant reduction of 46.8 and 53.13% respectively (P< 0.05). It is recommended to carry out more studies to determine if higher doses of chloroformic extract or its administration in combination with other antichagasic drugs allows a better response over the intracellular stage ofT. cruziin infected animal models and determine if the chloroform extract ofC. papayacould be considered as an alternative for treatment during the indeterminate and chronic phase of the infection.


2011 ◽  
Vol 40 (3) ◽  
pp. 1131-1147 ◽  
Author(s):  
Frédéric Raymond ◽  
Sébastien Boisvert ◽  
Gaétan Roy ◽  
Jean-François Ritt ◽  
Danielle Légaré ◽  
...  

2011 ◽  
Vol 2011 ◽  
pp. 1-13 ◽  
Author(s):  
Carolina Macedo Koeller ◽  
Norton Heise

The protozoan parasite Trypanosoma cruzi is the causative agent of human Chagas disease, for which there currently is no cure. The life cycle of T. cruzi is complex, including an extracellular phase in the triatomine insect vector and an obligatory intracellular stage inside the vertebrate host. These phases depend on a variety of surface glycosylphosphatidylinositol-(GPI-) anchored glycoconjugates that are synthesized by the parasite. Therefore, the surface expression of GPI-anchored components and the biosynthetic pathways of GPI anchors are attractive targets for new therapies for Chagas disease. We identified new drug targets for chemotherapy by taking the available genome sequence information and searching for differences in the sphingolipid biosynthetic pathways (SBPs) of mammals and T. cruzi. In this paper, we discuss the major steps of the SBP in mammals, yeast and T. cruzi, focusing on the IPC synthase and ceramide remodeling of T. cruzi as potential therapeutic targets for Chagas disease.


2007 ◽  
Vol 51 (8) ◽  
pp. 3030-3032 ◽  
Author(s):  
Adriano C. Coelho ◽  
Nadine Messier ◽  
Marc Ouellette ◽  
Paulo C. Cotrim

ABSTRACT Pentamidine is a second-line agent in the treatment of leishmaniasis whose mode of action and resistance mechanism are not well understood. In this work, we show that the intracellular ABC protein PRP1 (pentamidine resistance protein 1) (ABCC7) can confer resistance to pentamidine in Leishmania sp. parasites in the intracellular stage.


2006 ◽  
Vol 8 (2) ◽  
pp. 401-409 ◽  
Author(s):  
Vanina A. Campo ◽  
Carlos A. Buscaglia ◽  
Javier M. Di Noia ◽  
Alberto Carlos C. Frasch

Sign in / Sign up

Export Citation Format

Share Document